Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and offering expenses payable by Werewolf, are expected to be approximately $120.0 million. Werewolf has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Werewolf.
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Arcellx Announces Executive Appointments
Arcellx, Inc.April 19, 2021 GMT
GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs and Neeraj Teotia has been named Chief Commercial Officer where he will have responsibility for marketing, sales, and health economics and reimbursement.
“We are excited to strengthen our leadership team with the additions of Chris and Neeraj as they bring significant expertise to Arcellx and reflect our values and culture. They will lead two critically important areas advancing our clinical programs to meet all requirements for regulatory approvals and ensu
Published: Apr 19, 2021
GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) -Arcellx Inc. a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs and Neeraj Teotia has been named Chief Commercial Officer where he will have responsibility for marketing, sales, and health economics and reimbursement.
“We are excited to strengthen our leadership team with the additions of Chris and Neeraj as they bring significant expertise to Arcellx and reflect our values and culture. They will lead two critically important areas advancing our clinical programs to meet all requirements for regulatory approvals and ensuring successful commercialization post approval,” said Rami Elghandour, Chairman and Chief Executive Officer of Arcellx. “Chris will le